Ixempra
(Ixabepilone)ApprovedSmall molecule
Ixabepilone is used to treat advanced breast cancer, either alone or in combination with other chemotherapy drugs. It works by stopping cancer cells from dividing and growing.[2] Ixempra is currently approved and in use across 21 indications[4].[1]
Ixempra is one of 388 small molecule programs targeting Peritoneum Cancer. It is currently in Approved.
21
Indications
99
Total Trials
3
Active Trials
387
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 21 indications
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ixempra
RR-Pharm
Approved
Blenoxane
Bristol-Myers SquibbPreclinical
Spravato
WWim Janssens
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Bisphosphonate
AmgenPreclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer34 trials
Show 31 more trials
Prostate Cancer5 trials
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Terminated·—·Phase 2·NCT00672009·11 enrolled
Show 2 more trials
Patients With Advanced Solid Tumors4 trials
Metastatic Prostate Cancer3 trials
43 more indications
Kidney Cancer2 trials
Non-Small Cell Lung Cancer2 trials
Patients With Solid Tumors2 trials
Primary Peritoneal Cancer2 trials
Solid Tumors2 trials
Advanced Cancers2 trials
Pancreatic Cancer2 trials
Stomach Cancer2 trials
Biomarkers1 trial
Neoadjuvant Chemotherapy1 trial
Germ Cell Tumor1 trial
Recurrent or Refractory Solid Tumors1 trial
Advanced Cancer1 trial
Solid Malignancies1 trial
Recurrent Head and Neck Cancer1 trial
Advanced Malignancies1 trial
Lymphoma1 trial
Advanced Solid Tumors1 trial
Leiomyosarcoma1 trial
Gastric Cancer1 trial
Metastatic Colorectal Cancer1 trial
Lymphoproliferative Disorders1 trial
Lung Cancer1 trial
Squamous Cell Cancer of the Head and Neck1 trial
Leukemia1 trial
Glioma1 trial
Peripheral Neuropathy1 trial
Adult Solid Neoplasm1 trial
Endometrial Adenocarcinoma1 trial
Estrogen Receptor Negative1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Oct 16, 2007
IXEMPRA KIT
NDA NDA022065
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ixempra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ixabepilone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]